# 1. Financial Performance ## A. Key Figures * **Total Income:** **₹734.92 Mn** Q1 FY26 (+18.83% YoY) * PAT: ₹91.75 Mn (+19.67% YoY), 12.64% margin ## B. Revenue Growth * **Exceptional Top-Line Acceleration:** Revenue surged 83% YoY, reflecting strong demand momentum and successful market penetration. ## C. EBITDA & Margins * **Margin Resilience Amid Expansion:** Despite new center ramp-up costs, EBITDA and PAT margins held firm at 97% and 64%, underpinned by structural cost efficiency and minimal B2B-B2C margin divergence. * **Near-Term Margin Pressure:** New center losses of **₹3–4 Cr** weighed on EBITDA; excluding these, underlying EBITDA would have reached **₹27–28 Cr** versus reported ₹25 Cr. * **Path to Margin Expansion:** Operating leverage, higher throughput, and controlled HO expenses are expected to drive margin improvement as centers mature, though quarterly progression may be uneven. * **Cost Structure Visibility:** Rental costs represent 8–9% of revenue, embedded within 17% total other expenses, indicating disciplined overhead management. --- # 2. Volume & Revenue Mix ## A. Key Figures * **Overall EBITDA Margin:** **34%** (diluted by new center ramp-up) * **Volume Growth:** **25–26%** (H1 FY26) * **Revenue Growth:** **19%** (H1 FY26) * **B2B Revenue Mix:** Shift from **4%** to higher proportion due to new initiatives * **Tests per Patient:** **5–6** average, with upside potential from B2B ## B. Test Volume Growth * **Strong Volume Momentum:** Robust double-digit volume growth driven by network expansion, esoteric testing adoption, and B2B package penetration. * **Margin Dilution from Expansion:** New center additions—particularly eight centers under four months old—are currently loss-making, weighing on overall margin despite strong unit economics in mature centers. * **Growth Accounting:** Volume growth outpaces revenue growth, reflecting structural mix shift rather than pricing or operational inefficiency. ## C. B2B vs B2C Shift * **Structural B2B Inflection:** Strategic pivot toward B2B via genetic labs and corporate/PSU partnerships is reshaping revenue mix and increasing tests per patient. * **Diagnostic Chains Gaining Share:** Outpatient diagnostics increasingly routed through standalone centers due to geographic reach and specialization, displacing hospital-based testing beyond routine IPT needs. ## D. Revenue per Patient * **Pricing Pressure from Mix Shift:** Slight decline in revenue per patient reflects higher volume, lower-priced B2B and package-driven testing, despite **30–40% cost advantage** perception vs. hospitals. * **Volume-for-Margin Trade-off:** Revenue growth lagging volume underscores successful penetration of high-volume, lower ASP segments, particularly in corporate health programs. --- # 3. Network & Capacity ## A. Key Figures * **New Centers Opened:** **8** in Q1 FY26 (net addition of 6, total now **58** as of June 2025) * **Expansion Guidance:** **15–18** new centers planned on gross basis for FY26 ## B. New Center Expansion * **Aggressive Growth Execution:** Network expanded with **8 new centers** in Q1, including diverse formats (large, medium, small, PPP), reflecting disciplined rollout under concentric growth strategy. * **Strategic Closures & Replacements:** **3 centers closed** due to lease expiry and proximity overlap; **2 collection points** may be consolidated, optimizing footprint without disrupting volume. * **Fetomat Acquisition Pending Integration:** Addition of **2 centers** from acquisition not yet reflected in current count, to be included next quarter, supporting future growth pipeline. * **Competitive Landscape Intensifying:** Vijaya Diagnostics expanding hub network, signaling increased regional competition, particularly in high-potential markets. ## C. Center Maturity & Age * **Margins Scale with Maturity:** New centers initially dilutive but reach **~21% EBITDA margin** within 12–15 months; centers over two years deliver **strong 37% EBITDA margin**, validating long-term profitability model. * **Closed Centers Had Minimal Impact:** Underperforming legacy centers generated only **₹1.5–2.0 Mn/month** and were EBITDA-negative, but closure did not affect overall margin trajectory—new centers more than offset drag. ## D. Hub & PPP Model * **Structural Advantage in Advanced Diagnostics:** Independent centers benefit from broader specialist access, enabling superior delivery of **high-end imaging and advanced protocols**, differentiating service offering. * **First-Mover Edge in Regional Genomics:** Diagnostics remains regional in nature; company positioned as **early leader in regional genomic labs**, aiming to dominate localized markets through proximity and scale. --- # 4. Product & Segment Growth ## A. Key Figures * **Genomics Investment:** **₹22 Cr** in Suraksha + advanced testing (state-of-the-art lab) * **Incremental Revenue (Genomics):** **₹40–45 Cr** expected over next two years * Fetomat Revenue (Q1): ₹1.3–1.4 Cr in first quarter post-acquisition ## B. Genomics Launch * **First-Mover Advantage:** Launch of Suraksha Genomics establishes the **first comprehensive genomic lab in Eastern India**, capitalizing on underpenetrated regional demand and creating a platform for leadership in fetal and genomic medicine. * **Strategic Expansion:** Genomics integration drives **B2B partnerships** with major hospitals and academic institutions across East and Northeast India, enhancing reach and diagnostic ecosystem integration. * **Growth Trajectory:** Investment supports **strong double-digit incremental revenue expectations**, leveraging Suraksha’s regional scale and focus on rapid, accurate testing. ## C. Fetomat Acquisition * **Formal Entry into Genomic Medicine:** 63% acquisition of Fetomat Wellness marks strategic pivot into high-growth prenatal and genetic diagnostics, with synergies in women’s health and counseling. * **Immediate Revenue Contribution:** Asset accretive from onset, with **near-term revenue ramp** expected through integration into flagship centers. ## D. Fetal Medicine Scale * **Rapid Network Expansion:** Fetal medicine services scaling from 4 to **15–18 centers by FY '26**, enabling broader access and operational leverage across the region. * **B2B Segment Diversification:** Esoteric testing capabilities target hospitals, consultants, and pharma R&D, positioning the lab as a comprehensive solutions provider in high-complexity diagnostics. --- # 5. Technology & Innovation ## A. [NGS & Cytogenetics] * **Headline:** Launched **Suraksha Genomics**, a dedicated vertical for advanced genetic and molecular testing, featuring Cytogenetics and NGS across multiple platforms. * **Headline:** Operates the **largest cytogenetic lab in the region**, supported by microarray, Sanger sequencing, and multiple NGS platforms, with full test panels already live and delivering results. * **Headline:** High-end genomics testing remains concentrated in specialized labs due to hospital infrastructure and expertise gaps, creating a structural opportunity for centralized genomic providers. * **Headline:** Genomics currently focused on oncology and hematological cancers (e.g., leukemia), but poised for broad expansion across disease areas as personalized medicine accelerates. ## B. [Future Test Expansion] * **Headline:** Strategic roadmap includes **whole genome and metagenomic testing**, **AI-driven variant interpretation**, and **population-scale genomic screening programs** to capture next-wave innovation. * **Headline:** Genomics expected to transition from niche to **routine clinical use within 5–6 years**, driven by individual phenotypic variation and falling costs. --- # 6. Talent & Operational Risks ## A. Genomics Manpower Shortage * **Headline:** Scaling genomics operations is primarily constrained by a **shortage of qualified manpower**, especially specialists skilled in interpreting **Next-Generation Sequencing (NGS) reports**. ## B. New Center Ramp Challenges * **Headline:** Despite hospital expansion into diagnostics, standalone diagnostic centers maintain dominance due to superior scale and expertise. * **Headline:** Competitive threats remain limited by the **regional, trust-driven nature of the diagnostics market**, which hampers rapid market entry and share capture by new players. --- # 7. Guidance & Outlook ## A. Key Figures * **Revenue Growth Guidance:** **15%** for current year * **EBITDA Margin Guidance:** **34%–35%** for current year * **Capex Plan:** **₹70 Cr** in FY'26, fully funded via internal accruals * Strategic Investment: INR45 odd crores allocated to genomics expansion ## B. Revenue & Margin Targets * **Margin Recovery Expected:** EBITDA margins anticipated to improve in Q2 on seasonal strength and center ramp-up, with commitment to sustain **~35% annual margin** target. * **Growth Drivers:** High-end esoteric tests represent strategic future growth lever, despite slow initial adoption; ongoing innovation to expand test menu. * **Management Confidence:** Leadership expresses intent to deliver better results by quarter-end, underpinned by seasonal tailwinds and operational improvements. ## C. Capex & Funding Plan * **Targeted Expansion:** Genomics to receive **₹45 Cr** of planned capex, signaling pivot toward advanced diagnostics beyond core pathology. * **Capital Discipline:** FY'26 capex fully self-funded; **no debt planned**, though equipment financing remains an option if needed. * **Project Funding Source:** **₹4 Cr** loss from vacated premises to be offset by government compensation, redeployed into ongoing capex.